# A UK audit of trial access and germline testing uptake in triple-negative breast cancer

Source: https://onco.cc/ideas/idea-tnbc-uk-trial-access-and-germline-testing-audit/  
OnCo record `idea-tnbc-uk-trial-access-and-germline-testing-audit` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Every triple-negative patient under 60 in the UK should be offered a BRCA test at diagnosis because the result now changes treatment, and many should be offered a trial, but no one publishes how many are. A national audit through existing cancer registration and genomic laboratory data would show the gap by region before anyone tries to close it.

## Summary

The UK and NHS page for triple-negative breast cancer names the specific referral, testing and funding gaps; this idea holds the published evidence behind an audit. What exists now: the OlympiA six-year update makes germline status a treatment decision with a survival benefit (hazard ratio 0.72); Atchley's series shows a triple-negative diagnosis itself predicts a BRCA1 variant in 57 percent of carriers; the ASCO, ASTRO and SSO guideline and NICE criteria both support testing at diagnosis; the POSH cohort shows the UK can assemble national young-onset breast cancer data with ethnicity and outcome. What is missing is a published figure for the proportion of eligible triple-negative patients tested within the neoadjuvant window, when the result can change surgery and adjuvant therapy, and for the proportion offered a trial, by region and ethnicity.

## Fields

- Kind: Idea
- Last checked: 2026-09-24
- Tags: tnbc-evidence
- Hypothesis: Linking cancer registration, genomic laboratory hub and trial recruitment records will show that fewer than 60 percent of eligible triple-negative patients in England are germline tested before surgery and that testing and trial offers vary more than twofold between regions, and publishing the figures annually will raise both within two years.
- Rationale: Audit and publication is the cheapest lever the NHS has, and for triple-negative disease the test result carries a proven survival benefit and the trials carry the new standards of care.
- Proposed test: Retrospective linkage for the 2023 to 2025 diagnostic cohort, then annual publication of tested-before-surgery and trial-offer rates by cancer alliance and ethnicity, with a target and a named owner.
- Maturity: speculative
- Actor: data

## Notes

- The UK and NHS page for triple-negative breast cancer records the gaps this audit would measure: no published rate of germline testing within the neoadjuvant window, no published trial-offer rate, and NHS England pages that could not be read on 24 September 2026.

## Sources

- OlympiA six-year update (Ann Oncol 2026): https://europepmc.org/article/MED/42636977
- Atchley et al.: BRCA status and triple-negative breast cancer (J Clin Oncol 2008): https://europepmc.org/article/MED/18779615

## Connected records

- ideas: [Close the gap between who gets triple-negative breast cancer and who is in its trials](https://onco.cc/ideas/idea-tnbc-disparities-in-access-and-outcomes/)
- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)
- institutions: [Cancer Research UK](https://onco.cc/institutions/cruk/), [National Institute for Health and Care Excellence](https://onco.cc/institutions/nice/)
- trials: [OlympiA](https://onco.cc/trials/olympia/)
- bottlenecks: [Data silos](https://onco.cc/bottlenecks/b-data-silos/), [Fragmented care and guideline gaps](https://onco.cc/bottlenecks/b-care-fragmentation/), [Inherited risk is mostly unidentified](https://onco.cc/bottlenecks/b-hereditary-risk/)
- key papers: [Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer](https://onco.cc/key-papers/paper-atchley-brca-status-triple-negative-jco-2008/), [Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study](https://onco.cc/key-papers/paper-copson-posh-ethnicity-young-breast-cancer-uk-bjc-2014/), [Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline](https://onco.cc/key-papers/paper-asco-hereditary-breast-cancer-guideline-jco-2020/), [Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial](https://onco.cc/key-papers/paper-olympia-6-year-update-ann-oncol-2026/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-tnbc-uk-trial-access-and-germline-testing-audit.json